NEUROENDOCRINE NEOPLASM
Clinical trials for NEUROENDOCRINE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE NEOPLASM trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Treat gut tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of slow-growing gut and pancreas cancer called neuroendocrine tumors. The goal is to find the safest dose and see if the combination shrinks tum…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Major trial pits two drug cocktails against Hard-to-Treat cancers
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better slows …
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat carcinoid tumors
Disease control OngoingThis Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy aims to shrink Hard-to-Treat neuroendocrine liver tumors
Disease control OngoingThis phase 2 pilot study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with liver-directed treatments (like embolization or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink tumors in people with well-differentiated neuroendocrine tum…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE2 • Sponsor: Nicholas Fidelman, MD • Aim: Disease control
Last updated Jun 26, 2026 13:09 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC